MedPath

FDA Approves Phase 2 Trial Modification for Abion's Novel Lung Cancer Combination Therapy

The FDA has approved modifications to the Phase 2 clinical trial for vabametkib, Abion's c-MET targeted anticancer drug, in combination with lazertinib for non-small cell lung cancer patients. The trial will evaluate this novel combination therapy in patients who have developed resistance to EGFR-targeted treatments, addressing a significant unmet need in NSCLC treatment.

Abion has received FDA approval for modifications to its Phase 2 clinical trial investigating vabametkib (ABN401) in combination with lazertinib for advanced non-small cell lung cancer (NSCLC) patients. The trial specifically targets patients who have developed resistance to EGFR-targeted therapies due to c-MET overexpression or amplification.
The comprehensive Phase 2 study will enroll 138 patients across multiple sites in Korea, Taiwan, and the United States, structured in three distinct parts. The trial design demonstrates a methodical approach to establishing both safety and efficacy parameters for this novel combination therapy.

Trial Design and Objectives

The clinical investigation is strategically divided into three sequential parts:
  • Part 1 focuses on dose-finding and safety assessment of the combination therapy
  • Part 2 aims to determine the optimal dosing strategy by evaluating efficacy across various dose combinations
  • Part 3 will compare the established optimal combination against current standard treatment options

Addressing a Critical Treatment Gap

According to Abion, approximately 30% of NSCLC patients treated with EGFR-targeting drugs develop resistance through c-MET overexpression or amplification. The combination of vabametkib and lazertinib (marketed as Lazcluze in the US) represents a strategic approach to simultaneously target both c-MET and EGFR signaling pathways.
"This clinical modification approval enables us to move forward with full-scale clinical trials with lazertinib," stated an Abion representative. "The potential for a first-in-class innovative treatment is significant, as no drugs have yet been approved for this specific combination therapy."

Market Potential

The market opportunity for successful c-MET inhibitors appears substantial. According to Evaluate Pharma, the global c-MET inhibitor market is expected to reach approximately USD 4.726 billion by 2026, highlighting the significant commercial potential for effective therapies in this space.
The development of this combination therapy represents a potentially important advance in addressing treatment resistance in NSCLC, a persistent challenge in oncology. By targeting two critical pathways simultaneously, this approach could offer new hope for patients who have exhausted current treatment options.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

AbbVie's Telisotuzumab Vedotin Shows Promise in c-Met Overexpressing NSCLC

AbbVie's telisotuzumab vedotin (Teliso-V) demonstrated a 35% overall response rate in patients with high c-Met expression in the LUMINOSITY trial.
The FDA granted breakthrough therapy designation to Teliso-V, highlighting its potential to significantly improve outcomes in NSCLC patients.

FDA Approves Companion Diagnostic for Tepotinib in mNSCLC with MET Exon 14 Skipping Alterations

The FDA approved FoundationOne Liquid CDx as a companion diagnostic for tepotinib, aiding in identifying mNSCLC patients with MET exon 14 skipping alterations.
Tepotinib received regular approval in February 2024 for mNSCLC patients with MET exon 14 skipping alterations, following an earlier accelerated approval in 2021.

AstraZeneca and Daiichi Sankyo Seek FDA Approval for Datopotamab Deruxtecan in EGFR-Mutated NSCLC

AstraZeneca and Daiichi Sankyo have submitted a Biologics License Application (BLA) to the FDA for datopotamab deruxtecan (Dato-DXd).
The BLA targets the treatment of locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) in patients who have previously received systemic therapies.

FDA Approves Zolbetuximab for HER2-Negative Gastric and GEJ Adenocarcinoma

The FDA has approved zolbetuximab-clzb (Vyloy) in combination with chemotherapy for first-line treatment of CLDN18.2-positive, HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Approval was based on the SPOTLIGHT and GLOW trials, which demonstrated statistically significant improvements in progression-free and overall survival.

Ziftomenib Shows Promise in Treatment-Resistant Acute Myeloid Leukemia

Ziftomenib, an oral menin inhibitor, demonstrates efficacy in relapsed/refractory AML patients, offering a new treatment avenue.
The KOMET-001 trial reveals a partial or complete response in about a third of patients with multiple prior therapies.

AbbVie Seeks Accelerated FDA Approval for Telisotuzumab Vedotin in c-Met Overexpressing NSCLC

AbbVie has submitted a Biologics License Application (BLA) to the FDA for telisotuzumab vedotin to treat NSCLC with c-Met protein overexpression.
The BLA is supported by Phase 2 LUMINOSITY trial data, which showed promising overall response rates in c-Met high and intermediate patients.

Annamycin Plus Cytarabine Shows Promise in AML Treatment: FDA Review Complete

Moleculin Biotech completed an end-of-phase 2 meeting with the FDA for annamycin combined with cytarabine in acute myeloid leukemia (AML).
A phase 1b/2 trial showed a 45% composite complete remission rate in efficacy-evaluable AML patients treated with the combination.

Sunvozertinib Granted FDA Breakthrough Therapy Designation for First-Line EGFR Exon 20 Insertion-Positive NSCLC

The FDA has granted Breakthrough Therapy Designation to sunvozertinib for first-line treatment of advanced NSCLC with EGFR exon 20 insertion mutations.
The designation is based on Phase I/II WU-KONG1 trial results, which showed a 78.6% objective response rate and 12.4 months median progression-free survival.

FDA Approves Novartis' Tafinlar + Mekinist Combo for BRAF V600E-Mutated Solid Tumors

The FDA granted accelerated approval to Novartis' Tafinlar and Mekinist combination for advanced solid tumors harboring the BRAF V600E mutation after prior therapy and no alternative options.
This marks the first BRAF/MEK inhibitor approved for pediatric patients, expanding its use to individuals as young as six years old.

FDA Approves Fourth ALK Inhibitor for Lung Cancer

The FDA has approved brigatinib (Alunbrig) for treating certain patients with metastatic non-small cell lung cancer (NSCLC) driven by ALK gene mutations, especially those not responding to crizotinib. This approval is based on the phase II ALTA clinical trial results, showing significant tumor shrinkage in patients.

Reference News

[1]
Abion's c-MET targeted anticancer drug: Phase 2 change approved by FDA, Lazertinib ...
thebionews.net · Dec 30, 2024

Abion received FDA approval to modify phase 2 trials for 'vabametkib,' targeting c-MET in NSCLC patients resistant to EG...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy